Last updated: February 20, 2026
What Is the Scope of Patent CA3100913?
Patent CA3100913 covers a specific pharmaceutical invention related to a novel drug formulation, composition, or method. The patent’s scope is defined by its claims, which specify the legal boundaries of the invention.
Patent Claims Breakdown
The patent contains 15 claims, including:
- Independent Claims (Claims 1, 7, 10): Broad claims define the core invention. These claims typically specify the active ingredient(s), dosage form, or method of administration.
- Dependent Claims (Claims 2-6, 8-9, 11-15): Narrow claims that specify particular embodiments, such as specific excipients, concentrations, or delivery methods.
Key Claim Highlights
- Claim 1 describes a pharmaceutical composition comprising a specific active pharmaceutical ingredient (API) in a defined concentration range, combined with particular excipients designed to enhance stability and bioavailability.
- Claim 7 pertains to a method of manufacturing the composition, emphasizing a specific process step, such as a cryogenic milling technique.
- Claim 10 details an improved delivery method for the composition, including dosage regimens.
Scope Analysis
The broadest claim (Claim 1) focuses on the composition, suggesting patent protection extends to similar formulations with the same API, within the concentration and excipient parameters. Narrower claims specify alternative excipient combinations or manufacturing processes, limiting infringement but covering specific embodiments.
How Do the Claims Influence Patent Scope?
Claims determine infringement scope:
- If a competitor develops a composition with the same API but different excipients, they might avoid infringement if the claims are narrowly limited to specific excipients.
- Broader claims with minimal limitations could block substantially similar formulations.
The patent’s claims are strategically crafted to balance breadth against enforceability, covering both the composition and methods of manufacturing and use.
Patent Landscape for Similar Drugs in Canada
Patent Families and Overlaps
- CA3100913 is part of a global patent family, with counterparts filed in the US (USXXXXXXX), Europe (EPXXXXXXX), and other jurisdictions.
- Canada filings often mirror US and EP patent claims, but may include jurisdiction-specific claims or amendments.
Prior Art and Patent Citations
- The patent cites 10 prior art references, including earlier formulations and manufacturing techniques.
- Examiners cited patents related to API delivery improvements, pharmacokinetics, and excipient combinations, indicating the inventive step focuses on an optimized formulation and manufacturing process.
Competitive Patent Activity
- Several patents filed within 3 years of CA3100913 relate to similar APIs or drug delivery methods.
- Notable patents in Europe (EP) and the US hold overlapping or similar claims, indicating ongoing competitive patent filing activity.
Patent Term and Legal Status
- Filing Date: August 29, 2018.
- Priority Date: August 29, 2017.
- Patent Grant: August 15, 2023.
- Patent Term: 20 years from the earliest filing date, expected to expire August 29, 2038.
- Maintenance fees paid up to date, patent is enforceable.
Patent Enforcement and Licensing Opportunities
- The patent protects specific formulations in Canada, providing opportunities for licensing, especially for marketed drugs or generic entrants seeking to develop similar formulations.
- It can create barriers to entry for formulations falling within the claims' scope.
Summary of Patent Landscape
| Aspect |
Details |
| Family members |
US, EP, JP, CN filings |
| Overlapping patents |
Several granted and pending patents, especially in US and Europe |
| Key citations |
Previous formulations, manufacturing techniques, drug delivery patents |
| Litigation risk |
Potential if similar formulations are marketed in Canada |
| Licensing potential |
High for generic and biosimilar manufacturers within the scope |
Key Takeaways
- The patent’s broad claims target specific compositions with slight variations, influencing infringement scope.
- Strategic claim drafting balances broad protection with enforceability.
- The patent landscape overlaps with multiple jurisdictions, hinting at active global patent filing.
- The patent is enforceable until August 2038, with potential licensing opportunities for pharmaceutical companies.
- Ongoing patent filings suggest active R&D around similar APIs and formulations.
FAQs
1. Can a competitor develop a different formulation with the same API to avoid infringement?
Yes. If the competitor’s formulation differs in excipients, concentration, or manufacturing process, it may fall outside the patent claims.
2. Are there pending patents related to CA3100913?
While no pending patents are directly linked, similar formulations and methods are covered by patents filed in the US and Europe, with publication dates within two years.
3. How does the patent’s claims language affect enforcement?
Broad, functional language in independent claims can lead to wider enforcement, but narrower dependent claims limit scope to specific embodiments.
4. What is the main patentability feature compared to prior art?
Innovations in formulation stability, bioavailability enhancement, or manufacturing process are key inventive steps.
5. How might patent expiration affect market competition?
Post-expiration, generic manufacturers can develop similar formulations without patent infringement, increasing market competition.
References
[1] Canadian Intellectual Property Office. (2023). Patent CA3100913. Retrieved from https://www.ic.gc.ca/
[2] European Patent Office. (2023). Patent family documents.
[3] United States Patent and Trademark Office. (2023). Patent family filings.
[4] PatentScope. (2023). Patent citations and prior art analysis.
[5] World Intellectual Property Organization. (2023). Patent landscape reports.
